01.31.23
Pfizer
4Q Revenues: $24.3 billion (+2%)
4Q Earnings: $5.0 billion (+47%)
YTD Revenues: $100.3 billion (+23%)
YTD Earnings: $31.4 billion (+43%)
Comments: Growth was primarily driven by Covid-19 products: Comirnaty sales were $11.3 billion in the quarter, down 9% and $37.8 billion for the year, up 3%. Paxlovid sales were $1.8 billion in the quarter and $18.9 billion for the year. Excluding contributions from Paxlovid and Comirnaty, revenues in the quarter grew $571 million, or 5%.
Primary Care sales were $17.3 billion in the quarter, up 7% and $73.0 billion for the year, up 40%.
Specialty Care sales were down 11% to $3.6 billion in the quarter and down 9% to $13.8 billion for the year.
Oncology sales were down 7% to $3.0 billion in the quarter and down 2% to $12.1 billion for the year.
Prevnar family sales in the quarter were $1.7 billion, up 33% and $6.3 billion for the year, up 20%. In the U.S., sales were up 79%, driven primarily by demand and favorable timing of Centers for Disease Control and Prevention (CDC) purchasing of the pediatric indication.
Revenues from recently acquired products, Nurtec ODT/Vydura and Oxbryta, contributed $211 million and $73 million in global revenues, respectively.
Vyndaqel family sales were up 21% to $680 million in the quarter and $2.4 billion for the year.
Eliquis sales in the quarter were $1.5 billion, down 1% and $6.5 billion for the year, up 9%.
Enbrel sales were down 21% in the quarter to $236 million and down 15% for the year to $1.0 billion.
Xeljanz sales were down 32% to $493 million in the quarter and down 27% to $1.8 billion for the year.
Sutent sales were down 56% in the quarter to $60 million and down 48% to $347 million for the year, primarily driven by lower demand in Europe following loss of exclusivity in January 2022.
Pfizer CentreOne revenues were $368 million in the quarter, down 4% and $1.3 billion for the year, down 22%. Pfizer CentreOne includes revenues from Pfizer’s contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech. Revenues related to Comirnaty manufacturing activities totaled $80 million and $188 million for the fourth quarter and full-year 2022, respectively, and $46 million and $320 million for the fourth-quarter and full-year 2021, respectively.
4Q Revenues: $24.3 billion (+2%)
4Q Earnings: $5.0 billion (+47%)
YTD Revenues: $100.3 billion (+23%)
YTD Earnings: $31.4 billion (+43%)
Comments: Growth was primarily driven by Covid-19 products: Comirnaty sales were $11.3 billion in the quarter, down 9% and $37.8 billion for the year, up 3%. Paxlovid sales were $1.8 billion in the quarter and $18.9 billion for the year. Excluding contributions from Paxlovid and Comirnaty, revenues in the quarter grew $571 million, or 5%.
Primary Care sales were $17.3 billion in the quarter, up 7% and $73.0 billion for the year, up 40%.
Specialty Care sales were down 11% to $3.6 billion in the quarter and down 9% to $13.8 billion for the year.
Oncology sales were down 7% to $3.0 billion in the quarter and down 2% to $12.1 billion for the year.
Prevnar family sales in the quarter were $1.7 billion, up 33% and $6.3 billion for the year, up 20%. In the U.S., sales were up 79%, driven primarily by demand and favorable timing of Centers for Disease Control and Prevention (CDC) purchasing of the pediatric indication.
Revenues from recently acquired products, Nurtec ODT/Vydura and Oxbryta, contributed $211 million and $73 million in global revenues, respectively.
Vyndaqel family sales were up 21% to $680 million in the quarter and $2.4 billion for the year.
Eliquis sales in the quarter were $1.5 billion, down 1% and $6.5 billion for the year, up 9%.
Enbrel sales were down 21% in the quarter to $236 million and down 15% for the year to $1.0 billion.
Xeljanz sales were down 32% to $493 million in the quarter and down 27% to $1.8 billion for the year.
Sutent sales were down 56% in the quarter to $60 million and down 48% to $347 million for the year, primarily driven by lower demand in Europe following loss of exclusivity in January 2022.
Pfizer CentreOne revenues were $368 million in the quarter, down 4% and $1.3 billion for the year, down 22%. Pfizer CentreOne includes revenues from Pfizer’s contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech. Revenues related to Comirnaty manufacturing activities totaled $80 million and $188 million for the fourth quarter and full-year 2022, respectively, and $46 million and $320 million for the fourth-quarter and full-year 2021, respectively.
